Robert L. Shepard
YOU?
Author Swipe
View article: Designing a Holistic Digital Fabrication Interdisciplinary Curriculum for Elementary School Learners
Designing a Holistic Digital Fabrication Interdisciplinary Curriculum for Elementary School Learners Open
This paper describes a pilot design process for STEM education, going beyond the traditional STEM focus to incorporate digital fabrication, disciplinary and transversal skills, project-based learning pedagogy, an Understanding by Design cu…
View article: Figure S4 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Figure S4 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration Open
A and B, NCI-H1155 and HCT116 cells were grown and treated in duplicates with LSN3154567 (100 nM), respectively, as described (Materials and Methods) and apoptosis was analyzed as described above.
View article: Figure S5 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Figure S5 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration Open
The concentrations of LSN3154567 in the dog plasma samples.
View article: Supplementary Figure Legend from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Supplementary Figure Legend from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts Open
PDF file - 72K
View article: Data from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Data from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts Open
LY2334737, an oral prodrug of gemcitabine, is cleaved in vivo, releasing gemcitabine and valproic acid. Oral dosing of mice results in absorption of intact prodrug with slow systemic hydrolysis yielding higher plasma levels of LY233…
View article: Supplementary Figure 1 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Supplementary Figure 1 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts Open
PDF file - 316K, Supplementary Figure 1 - in vivo study body weights
View article: Supplementary Figure 2 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Supplementary Figure 2 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts Open
PDF file - 112K, Supplementary Figure 2 - in vivo study body weights
View article: Figure S4 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Figure S4 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration Open
A and B, NCI-H1155 and HCT116 cells were grown and treated in duplicates with LSN3154567 (100 nM), respectively, as described (Materials and Methods) and apoptosis was analyzed as described above.
View article: Supplementary Figure Legend from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Supplementary Figure Legend from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts Open
PDF file - 72K
View article: Supplementary Figure 1 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Supplementary Figure 1 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts Open
PDF file - 316K, Supplementary Figure 1 - in vivo study body weights
View article: Figure S5 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Figure S5 from Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration Open
The concentrations of LSN3154567 in the dog plasma samples.
View article: Supplementary Figure 2 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Supplementary Figure 2 from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts Open
PDF file - 112K, Supplementary Figure 2 - in vivo study body weights
View article: Data from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts
Data from Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts Open
LY2334737, an oral prodrug of gemcitabine, is cleaved in vivo, releasing gemcitabine and valproic acid. Oral dosing of mice results in absorption of intact prodrug with slow systemic hydrolysis yielding higher plasma levels of LY233…
View article: Dual-mode self-validating resistance/Johnson noise thermometer system
Dual-mode self-validating resistance/Johnson noise thermometer system Open
A dual-mode Johnson noise and DC resistance thermometer capable of use in control systems where prompt indications of temperature changes and long term accuracy are needed. A resistance-inductance-capacitance (RLC) tuned circuit produces a…
View article: Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells
Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells Open